Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q1 2023
Institutional positions in Caribou Biosciences, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 126
- −6 vs. Q4 2022
- Shares held
- 45.0M
- +1.40M (+3.2%) vs. Q4 2022
- Total value
- $238.3M
- −$35.5M (−13.0%) vs. Q4 2022
- New holders
- 13
- 49 more added
- Sold out
- 19
- 33 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRBU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $84.8M |
| Q1 2026 | 137 | $71.3M |
| Q4 2025 | 124 | $58.8M |
| Q3 2025 | 117 | $87.0M |
| Q2 2025 | 129 | $51.2M |
| Q1 2025 | 131 | $45.8M |
| Q4 2024 | 133 | $93.1M |
| Q3 2024 | 129 | $103.1M |
| Q2 2024 | 140 | $87.6M |
| Q1 2024 | 151 | $343.0M |
| Q4 2023 | 144 | $395.8M |
| Q3 2023 | 126 | $338.5M |
| Q2 2023 | 121 | $185.5M |
| Q1 2023 | 126 | $238.3M |
| Q4 2022 | 133 | $273.8M |
| Q3 2022 | 113 | $456.8M |
| Q2 2022 | 120 | $203.0M |
| Q1 2022 | 104 | $313.2M |
| Q4 2021 | 93 | $464.7M |
| Q3 2021 | 88 | $704.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Caribou Biosciences, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nuveen Asset Management, LLC | 292,964 | $1.56M | 0.00% | −13,922−4.5% | Reduced |
| Goldman Sachs Group Inc | 313,769 | $1.67M | 0.00% | −39,128−11.1% | Reduced |
| Millennium Management LLC | 325,015 | $1.73M | 0.00% | +84,972+35.4% | Added |
| Charles Schwab Investment Management Inc | 410,449 | $2.18M | 0.00% | +5,547+1.4% | Added |
| International Biotechnology Trust PLC | 457,892 | $2.43M | 0.68% | +200,000+77.6% | Added |
| 72 Investment Holdings, LLC | 474,067 | $2.52M | 1.19% | 00.0% | Unchanged |
| Northern Trust Corp | 529,005 | $2.81M | 0.00% | −5,482−1.0% | Reduced |
| Memorial Sloan Kettering Cancer Center | 544,196 | $2.89M | 8.86% | 00.0% | Unchanged |
| Tekla Capital Management LLC | 567,147 | $3.01M | 0.11% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 602,978 | $3.20M | 0.00% | +2,881+0.5% | Added |
| Maverick Capital LtdSuperinvestorMaverick Capital | 652,542 | $3.46M | 0.09% | 00.0% | Unchanged |
| Assenagon Asset Management S.A. | 843,025 | $4.48M | 0.02% | −11,713−1.4% | Reduced |
| FIL Ltd | 860,666 | $4.57M | 0.01% | 00.0% | Unchanged |
| Alkeon Capital Management LLC | 1,054,645 | $5.60M | 0.04% | −3,958−0.4% | Reduced |
| Geode Capital Management, LLC | 1,069,624 | $5.68M | 0.00% | +38,637+3.7% | Added |
| Morgan Stanley | 1,249,248 | $6.63M | 0.00% | +20,081+1.6% | Added |
| FMR LLC | 1,443,823 | $7.67M | 0.00% | +777+0.1% | Added |
| Pictet Asset Management SA | 2,066,176 | $11.0M | 0.01% | −487,702−19.1% | Reduced |
| Elmwood Wealth Management, Inc. | 2,364,240 | $12.6M | 5.93% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,606,061 | $13.8M | 0.00% | +25,844+1.0% | Added |
| Bank of America Corp | 2,632,385 | $14.0M | 0.00% | +788,483+42.8% | Added |
| Rokos Capital Management LLP | 2,748,139 | $14.1M | 1.23% | 00.0% | Unchanged |
| Avidity Partners Management LP | 2,758,600 | $14.6M | 0.49% | −124,000−4.3% | Reduced |
| State Street Corp | 3,355,292 | $17.8M | 0.00% | +156,399+4.9% | Added |
| BlackRock Inc. | 4,754,563 | $25.2M | 0.00% | +32,480+0.7% | Added |
| PFM Health Sciences, LP | 5,012,118 | $26.6M | 1.23% | +552,335+12.4% | Added |
| Shelton Capital Management | 0 | $0 | 0.00% | −160,700−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −121,924−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −76,657−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −46,674−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −29,997−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −24,025−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −17,442−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −14,216−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −13,900−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −12,801−100.0% | Sold out |
| Boulder Hill Capital Management LP | 0 | $0 | 0.00% | −11,400−100.0% | Sold out |
| Arcus Capital Partners, LLC | 0 | $0 | 0.00% | −3,200−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −661−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −530−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −247−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −172−100.0% | Sold out |
| Itau Unibanco Holding S.A. | 0 | $0 | 0.00% | −96−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −57−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Sargent Bickham Lagudis LLC | – | – | – | – | Not filed |